Testing effectiveness (Phase 2)Not Yet RecruitingNCT07034508
What this trial is testing
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 134